Annals of Oncology

Heine H. Hansen, 19382011: a European oncologist
pp. 283-284(2)
Author: Tonato, M.

Screening mammography and socioeconomic inequalities in breast cancer survival
pp. 285-286(2)
Authors: Woods, L. M.; Sasieni, P.; Rachet, B.

A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk
pp. 287-297(11)
Authors: Tramacere, I.; Pelucchi, C.; Bagnardi, V.; Rota, M.; Scotti, L.; Islami, F.; Corrao, G.; Boffetta, P.; La Vecchia, C.; Negri, E.

Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes
pp. 298-304(7)
Authors: Greco, F. A.; Oien, K.; Erlander, M.; Osborne, R.; Varadhachary, G.; Bridgewater, J.; Cohen, D.; Wasan, H.

CMF revisited in the 21st century
pp. 305-311(7)
Authors: Munzone, E.; Curigliano, G.; Burstein, H. J.; Winer, E. P.; Goldhirsch, A.

A meta-analysis of coffee consumption and pancreatic cancer
pp. 311-318(8)
Authors: Turati, F.; Galeone, C.; Edefonti, V.; Ferraroni, M.; Lagiou, P.; La Vecchia, C.; Tavani, A.

Does an organised screening programme reduce the inequalities in breast cancer survival?
pp. 319-323(5)
Authors: Puliti, D.; Miccinesi, G.; Manneschi, G.; Buzzoni, C.; Crocetti, E.; Paci, E.; Zappa, M.

Breast cancer subtypes and outcome after local and regional relapse
pp. 324-331(8)
Authors: Montagna, E.; Bagnardi, V.; Rotmensz, N.; Viale, G.; Renne, G.; Cancello, G.; Balduzzi, A.; Scarano, E.; Veronesi, P.; Luini, A.; Zurrida, S.; Monti, S.; Mastropasqua, M. G.; Bottiglieri, L.; Goldhirsch, A.; Colleoni, M.

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
pp. 331-337(7)
Authors: Miller, K. D.; ONeill, A.; Perez, E. A.; Seidman, A. D.; Sledge, G. W.

Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome
pp. 338-345(8)
Authors: Yerushalmi, R.; Tyldesley, S.; Kennecke, H.; Speers, C.; Woods, R.; Knight, B.; Gelmon, K. A.

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe dInvestigateurs Nationaux pour lEtude des Cancers Ovariens (GINECO)
pp. 346-352(7)
Authors: Lortholary, A.; Largillier, R.; Weber, B.; Gladieff, L.; Alexandre, J.; Durando, X.; Slama, B.; Dauba, J.; Paraiso, D.; Pujade-Lauraine, E.

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience
pp. 353-360(8)
Authors: Wozniak, A.; Rutkowski, P.; Piskorz, A.; Ciwoniuk, M.; Osuch, C.; Bylina, E.; Sygut, J.; Chosia, M.; Rys, J.; Urbanczyk, K.; Kruszewski, W.; Sowa, P.; Siedlecki, J.; Debiec-Rychter, M.; Limon, J.

External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer
pp. 361-367(7)
Authors: Kim, J. H.; Kim, H. S.; Seo, W. Y.; Nam, C. M.; Kim, K. Y.; Jeung, H. C.; Lai, J. F.; Chung, H. C.; Noh, S. H.; Rha, S. Y.

Small bowel adenocarcinoma copy number profiles are more closely related to colorectal than to gastric cancers
pp. 367-374(8)
Authors: Haan, J. C.; Buffart, T. E.; Eijk, P. P.; van de Wiel, M. A.; van Wieringen, W. N.; Howdle, P. D.; Mulder, C. J. J.; van de Velde, C. J.; Quirke, P.; Nagtegaal, I. D.; van Grieken, N. C. T.; Grabsch, H.; Meijer, G. A.; Ylstra, B.

Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer CaseControl Consortium (PanC4)
pp. 374-382(9)
Authors: Lucenteforte, E.; La Vecchia, C.; Silverman, D.; Petersen, G. M.; Bracci, P. M.; Ji, B. T.; Bosetti, C.; Li, D.; Gallinger, S.; Miller, A. B.; Bueno-de-Mesquita, H. B.; Talamini, R.; Polesel, J.; Ghadirian, P.; Baghurst, P. A.; Zatonski, W.; Fontham, E.; Bamlet, W. R.; Holly, E. A.; Gao, Y. T.; Negri, E.; Hassan, M.; Cotterchio, M.; Su, J.; Maisonneuve, P.; Boffetta, P.; Duell, E. J.

Lung cancer physicians referral practices for palliative care consultation
pp. 382-387(6)
Authors: Smith, C. B.; Nelson, J. E.; Berman, A. R.; Powell, C. A.; Fleischman, J.; Salazar-Schicchi, J.; Wisnivesky, J. P.

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
pp. 388-394(7)
Authors: Coudert, B.; Ciuleanu, T.; Park, K.; Wu, Y.-L.; Giaccone, G.; Brugger, W.; Gopalakrishna, P.; Cappuzzo, F.

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinomadata from the Czech registry
pp. 395-401(7)
Authors: Buchler, T.; Klapka, R.; Melichar, B.; Brabec, P.; Duek, L.; Vyzula, R.; Abrahamova, J.

The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population
pp. 401-405(5)
Authors: Yun, S. J.; Ha, Y. S.; Chae, Y.; Kim, J. S.; Kim, I. Y.; Kim, W. J.

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
pp. 406-410(5)
Authors: Galsky, M. D.; Chen, G. J.; Oh, W. K.; Bellmunt, J.; Roth, B. J.; Petrioli, R.; Dogliotti, L.; Dreicer, R.; Sonpavde, G.

Risk of second cancers in Waldenstrm macroglobulinemia
pp. 411-415(5)
Authors: Varettoni, M.; Tedeschi, A.; Arcaini, L.; Pascutto, C.; Vismara, E.; Orlandi, E.; Ricci, F.; Corso, A.; Greco, A.; Mangiacavalli, S.; Lazzarino, M.; Morra, E.

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
pp. 415-420(6)
Authors: Zinzani, P. L.; Tani, M.; Pulsoni, A.; De Renzo, A.; Stefoni, V.; Broccoli, A.; Montini, G. C.; Fina, M.; Pellegrini, C.; Gandolfi, L.; Cavalieri, E.; Torelli, F.; Scopinaro, F.; Argnani, L.; Quirini, F.; Derenzini, E.; Rossi, M.; Pileri, S.; Fanti, S.; Baccarani, M.

Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection
pp. 421-426(6)
Authors: Mya, D. H. T.; Han, S. T.; Linn, Y. C.; Hwang, W. Y. K.; Goh, Y. T.; Tan, D. C. L.

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation
pp. 427-435(9)
Authors: Fountzilas, G.; Ciuleanu, E.; Bobos, M.; Kalogera-Fountzila, A.; Eleftheraki, A. G.; Karayannopoulou, G.; Zaramboukas, T.; Nikolaou, A.; Markou, K.; Resiga, L.; Dionysopoulos, D.; Samantas, E.; Athanassiou, H.; Misailidou, D.; Skarlos, D.; Ciuleanu, T.

T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results
pp. 435-441(7)
Authors: Secondino, S.; Zecca, M.; Licitra, L.; Gurrado, A.; Schiavetto, I.; Bossi, P.; Locati, L.; Schiavo, R.; Basso, S.; Baldanti, F.; Maccario, R.; Locatelli, F.; Siena, S.; Pedrazzoli, P.; Comoli, P.

Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study
pp. 442-449(8)
Authors: Kotsakis, A.; Vetsika, E.-K.; Christou, S.; Hatzidaki, D.; Vardakis, N.; Aggouraki, D.; Konsolakis, G.; Georgoulias, V.; Christophyllakis, Ch.; Cordopatis, P.; Kosmatopoulos, K.; Mavroudis, D.

Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study
pp. 450-457(8)
Authors: Rousseau, B.; Loulergue, P.; Mir, O.; Krivine, A.; Kotti, S.; Viel, E.; Simon, T.; de Gramont, A.; Goldwasser, F.; Launay, O.; Tournigand, C.

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience
pp. 458-463(6)
Authors: Khasraw, M.; Holodny, A.; Goldlust, S. A.; DeAngelis, L. M.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
pp. 463-471(9)
Authors: Soria, J.-C.; Cortes, J.; Massard, C.; Armand, J.-P.; De Andreis, D.; Ropert, S.; Lopez, E.; Catteau, A.; James, J.; Marier, J.-F.; Beliveau, M.; Martell, R. E.; Baselga, J.

Survival from common and rare cancers in Germany in the early 21st century
pp. 472-479(8)
Authors: Hiripi, E.; Gondos, A.; Emrich, K.; Holleczek, B.; Katalinic, A.; Luttmann, S.; Sirri, E.; Brenner, H.

Association between body mass index and the colorectal cancer risk in Japan: pooled analysis of population-based cohort studies in Japan
pp. 479-490(12)
Authors: Matsuo, K.; Mizoue, T.; Tanaka, K.; Tsuji, I.; Sugawara, Y.; Sasazuki, S.; Nagata, C.; Tamakoshi, A.; Wakai, K.; Inoue, M.; Tsugane, S.

Dietary cholesterol intake and cancer
pp. 491-500(10)
Authors: Hu, J.; La Vecchia, C.; de Groh, M.; Negri, E.; Morrison, H.; Mery, L.

Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network
pp. 501-508(8)
Authors: Stacchiotti, S.; Palassini, E.; Sanfilippo, R.; Vincenzi, B.; Arena, M. G.; Bochicchio, A. M.; De Rosa, P.; Nuzzo, A.; Turano, S.; Morosi, C.; Dei Tos, A. P.; Pilotti, S.; Casali, P. G.

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
pp. 508-516(9)
Authors: Grignani, G.; Palmerini, E.; Dileo, P.; Asaftei, S. D.; DAmbrosio, L.; Pignochino, Y.; Mercuri, M.; Picci, P.; Fagioli, F.; Casali, P. G.; Ferrari, S.; Aglietta, M.

Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome
pp. 517-523(7)
Authors: Penel, N.; Italiano, A.; Ray-Coquard, I.; Chaigneau, L.; Delcambre, C.; Robin, Y. M.; Bui, B.; Bertucci, F.; Isambert, N.; Cupissol, D.; Bompas, E.; Bay, J. O.; Duffaud, F.; Guillemet, C.; Blay, J. Y.

Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989
pp. 524-530(7)
Authors: Hollestein, L. M.; van den Akker, S. A. W.; Nijsten, T.; Karim-Kos, H. E.; Coebergh, J. W.; de Vries, E.

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
pp. 531-536(6)
Authors: von Moos, R.; Seifert, B.; Simcock, M.; Goldinger, S. M.; Gillessen, S.; Ochsenbein, A.; Michielin, O.; Cathomas, R.; Schlppi, M.; Moch, H.; Schraml, P. H.; Mjhic-Probst, D.; Mamot, C.; Schnewolf, N.; Dummer, R.

Toxicity burden score: a novel approach to summarize multiple toxic effects
pp. 537-541(5)
Authors: Lee, S. M.; Hershman, D. L.; Martin, P.; Leonard, J. P.; Cheung, Y. K.

Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data
pp. 542-543(2)
Authors: Ojha, R. P.; Thertulien, R.

The only thing I know is that I know nothing: 5-fluorouracil in human milk
pp. 543-544(2)
Authors: Peccatori, F. A.; Giovannetti, E.; Pistilli, B.; Bellettini, G.; Codacci-Pisanelli, G.; Losekoot, N.; Curigliano, G.; Azim, H. A.; Goldhirsch, A.; Peters, G. J.